ORKA-001 in Healthy Volunteers

Last updated: May 15, 2025
Sponsor: Oruka Therapeutics, Inc.
Overall Status: Active - Not Recruiting

Phase

1

Condition

Healthy Volunteers

Treatment

Placebo

ORKA-001

Clinical Study ID

NCT06698939
ORKA-001-111
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is a Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Healthy Participants.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  1. Healthy male or female participants

  2. 18 to 65 years (inclusive) with a body mass index (BMI) 18 to 32 kg/m2

  3. Willing and able to remain at the study site unit for the duration of theconfinement period and return for the outpatient visit/s defined in the protocol

  4. Using a highly effective method of contraception from admission through the end ofthe study.

  5. Willing to abstain from regular, continuous alcohol use or tobacco use as perprotocol

Exclusion

Key Exclusion Criteria:

  1. Any clinically significant medical condition or finding that, in the Investigator'sopinion, is likely to unfavorably alter the risk of study participation, confoundstudy results, or interfere with the study conduct or compliance.

  2. Known history of illicit drug use or drug abuse or harmful alcohol use

  3. Known history of frequent tobacco or vaping use within 2 years prior to Screening

  4. History of severe allergic reactions or hypersensitivity

  5. Actively nursing or lactating

  6. Use of investigational drug therapy within 30 days prior to enrollment

  7. Unable to comply with study requirements or in the opinion of the Investigatorshould not participate in this study.

Study Design

Total Participants: 24
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1
Study Start date:
December 19, 2024
Estimated Completion Date:
June 30, 2026

Study Description

This is a single center, phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, and pharmacokinetics (PK) of ORKA-001 in healthy volunteers. The study will enroll approximately 24 healthy volunteers. The ORKA-001 dose will be administered by a subcutaneous injection.

Connect with a study center

  • Oruka Therapeutics Investigative Site

    Christchurch,
    New Zealand

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.